IL284266B2 - History of (pyridin-2-yl)amine as an inhibitor of TGF-β in the cell R1 (ALK5) for cancer treatment - Google Patents
History of (pyridin-2-yl)amine as an inhibitor of TGF-β in the cell R1 (ALK5) for cancer treatmentInfo
- Publication number
- IL284266B2 IL284266B2 IL284266A IL28426621A IL284266B2 IL 284266 B2 IL284266 B2 IL 284266B2 IL 284266 A IL284266 A IL 284266A IL 28426621 A IL28426621 A IL 28426621A IL 284266 B2 IL284266 B2 IL 284266B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- mixture
- ring
- pharmaceutically acceptable
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785616P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/066993 WO2020139636A1 (en) | 2018-12-27 | 2019-12-17 | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284266A IL284266A (en) | 2021-08-31 |
| IL284266B1 IL284266B1 (en) | 2024-02-01 |
| IL284266B2 true IL284266B2 (en) | 2024-06-01 |
Family
ID=69185691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284266A IL284266B2 (en) | 2018-12-27 | 2019-12-17 | History of (pyridin-2-yl)amine as an inhibitor of TGF-β in the cell R1 (ALK5) for cancer treatment |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12102626B2 (https=) |
| EP (1) | EP3902796B1 (https=) |
| JP (2) | JP7515049B2 (https=) |
| KR (1) | KR102832376B1 (https=) |
| CN (1) | CN113348167B (https=) |
| AR (1) | AR117539A1 (https=) |
| AU (1) | AU2019417418B2 (https=) |
| BR (1) | BR112021007006A2 (https=) |
| CA (1) | CA3117838A1 (https=) |
| EA (1) | EA202191619A1 (https=) |
| ES (1) | ES2972516T3 (https=) |
| IL (1) | IL284266B2 (https=) |
| MX (1) | MX2021007738A (https=) |
| SG (1) | SG11202103457PA (https=) |
| TW (1) | TWI884934B (https=) |
| WO (1) | WO2020139636A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021259419A1 (en) | 2020-04-21 | 2022-11-10 | Lexicon Pharmaceuticals, Inc. | AAK1 inhibitors for use in treating viral infections |
| AU2021258128A1 (en) | 2020-04-21 | 2022-11-03 | Lexicon Pharmaceuticals, Inc. | 4-(3-(pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-5-yl)piperazine for use in the the treatment of COV-229E or COV-OC43 coronaviruses infections |
| CN113214111A (zh) * | 2021-04-30 | 2021-08-06 | 上海立科化学科技有限公司 | 3-（2-氰基苯基）丙酸及4-氰基-1-茚满酮的制备方法 |
| US12263576B2 (en) | 2021-08-19 | 2025-04-01 | Hyundai Mobis Co., Ltd. | Robot system for automated assembly of modular component |
| EP4464694A4 (en) * | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287857B6 (sk) | 2001-05-24 | 2012-01-04 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| JP5934782B2 (ja) * | 2011-05-04 | 2016-06-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アミノ−ピリジン含有脾臓チロシンキナーゼ（Ｓｙｋ）阻害薬 |
| WO2014048065A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| EP2934525B1 (en) * | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| WO2014155300A2 (en) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| PL3089971T3 (pl) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
| CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| WO2016201370A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP2018520201A (ja) | 2015-07-23 | 2018-07-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｇｆベーター受容体アンタゴニスト |
| WO2020103817A1 (zh) | 2018-11-20 | 2020-05-28 | 南京圣和药业股份有限公司 | TGF-βR1抑制剂及其应用 |
| JP7499284B2 (ja) | 2019-06-25 | 2024-06-13 | インベンティスバイオ カンパニー リミテッド | 複素環化合物、その製造方法及びその使用方法 |
| CN112707902B (zh) | 2020-03-23 | 2022-04-15 | 杭州阿诺生物医药科技有限公司 | TGF-β受体抑制剂 |
-
2019
- 2019-12-17 AU AU2019417418A patent/AU2019417418B2/en active Active
- 2019-12-17 MX MX2021007738A patent/MX2021007738A/es unknown
- 2019-12-17 BR BR112021007006-0A patent/BR112021007006A2/pt unknown
- 2019-12-17 EA EA202191619A patent/EA202191619A1/ru unknown
- 2019-12-17 KR KR1020217021785A patent/KR102832376B1/ko active Active
- 2019-12-17 IL IL284266A patent/IL284266B2/en unknown
- 2019-12-17 US US17/299,696 patent/US12102626B2/en active Active
- 2019-12-17 SG SG11202103457PA patent/SG11202103457PA/en unknown
- 2019-12-17 CN CN201980086920.0A patent/CN113348167B/zh active Active
- 2019-12-17 WO PCT/US2019/066993 patent/WO2020139636A1/en not_active Ceased
- 2019-12-17 EP EP19839715.0A patent/EP3902796B1/en active Active
- 2019-12-17 JP JP2021536757A patent/JP7515049B2/ja active Active
- 2019-12-17 ES ES19839715T patent/ES2972516T3/es active Active
- 2019-12-17 CA CA3117838A patent/CA3117838A1/en active Pending
- 2019-12-25 TW TW108147526A patent/TWI884934B/zh active
- 2019-12-27 AR ARP190103894A patent/AR117539A1/es unknown
-
2023
- 2023-01-17 JP JP2023005014A patent/JP2023052437A/ja active Pending
-
2024
- 2024-08-05 US US18/795,000 patent/US20240398776A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210110316A (ko) | 2021-09-07 |
| CN113348167B (zh) | 2026-01-09 |
| JP2022517730A (ja) | 2022-03-10 |
| US20220054465A1 (en) | 2022-02-24 |
| EP3902796C0 (en) | 2024-02-07 |
| EP3902796B1 (en) | 2024-02-07 |
| BR112021007006A2 (pt) | 2021-08-10 |
| SG11202103457PA (en) | 2021-05-28 |
| TWI884934B (zh) | 2025-06-01 |
| AU2019417418A1 (en) | 2021-04-15 |
| EP3902796A1 (en) | 2021-11-03 |
| EA202191619A1 (ru) | 2021-09-28 |
| CN113348167A (zh) | 2021-09-03 |
| KR102832376B1 (ko) | 2025-07-09 |
| CA3117838A1 (en) | 2020-07-02 |
| US12102626B2 (en) | 2024-10-01 |
| ES2972516T3 (es) | 2024-06-13 |
| TW202039436A (zh) | 2020-11-01 |
| AU2019417418B2 (en) | 2025-02-27 |
| AR117539A1 (es) | 2021-08-11 |
| IL284266B1 (en) | 2024-02-01 |
| MX2021007738A (es) | 2021-08-05 |
| JP2023052437A (ja) | 2023-04-11 |
| IL284266A (en) | 2021-08-31 |
| NZ775362A (en) | 2025-02-28 |
| JP7515049B2 (ja) | 2024-07-12 |
| US20240398776A1 (en) | 2024-12-05 |
| WO2020139636A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11498921B1 (en) | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | |
| JP7088983B2 (ja) | キナーゼ阻害剤としてのビアリールアミド化合物 | |
| AU2019417418B2 (en) | (pyridin-2-yl)amine derivatives as ΤGFβR1 (Alk5) inhibitors for the treatment of cancer | |
| AU2014367283B2 (en) | Maleimide derivatives as modulators of WNT pathway | |
| CN107922386B (zh) | 1,4-二取代的咪唑衍生物 | |
| TW202302537A (zh) | Ｌｐａ受體拮抗劑及其用途 | |
| TW202430178A (zh) | Ｐｃｓｋ９抑制劑及其使用方法 | |
| TW202229273A (zh) | 稠合雜芳基化合物及其作為CaMKII抑制劑之用途 | |
| CN120344517A (zh) | 作为pcsk9抑制剂的咪唑并[4,5-b]吡啶衍生物及其使用方法 | |
| WO2019189555A1 (ja) | 複素環化合物 | |
| TWI906428B (zh) | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 | |
| JP2024502106A (ja) | ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 | |
| EA043088B1 (ru) | Производные (пиридин-2-ил)амина в качестве ингибиторов tgf-бета r1 (alk5) для лечения злокачественных новообразований | |
| HK40063493A (en) | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | |
| HK40063493B (en) | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | |
| WO2025215153A1 (en) | Prmt5 inhibitors | |
| TW202428275A (zh) | Ｐｃｓｋ９抑制劑及其使用方法 | |
| US20260035361A1 (en) | Compounds for modulating hur (elavl1) | |
| CN117355517A (zh) | 大环胰高血糖素样肽1受体激动剂 |